hr

Hot Keywords
non-alcoholic fatty liver disease epidemiology microenvironment nonalcoholic steatohepatitis transplantation cholangiocarcinoma direct-acting antiviral immunotherapy hepatitis B hepatitis C liver resection imaging cancer stem cell diagnosis gene cirrhosis biomarker recurrence

Top
Topic: Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma

A special issue of Hepatoma Research

ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)

Submission deadline: 15 Feb 2023

Guest Editor(s)

  • Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA, FACS, FSSO, FRACS (Hon.)

    Professor and Chair, Department of Surgery;
    The Urban Meyer III and Shelley Meyer Chair for Cancer Research;
    Professor of Surgery, Oncology, and Health Services Management and Policy;
    Surgeon in Chief, The Ohio State University Wexner Medical Center;
    The Ohio State University, Wexner Medical Center, Columbus, OH, USA.

    Website | E-mail

Special Issue Introduction



Special Issue Webinar: Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma is a neoplasm of biliary epithelial origin, which is generally categorized according to anatomic localization: intra-hepatic (iCCA), hilar, and extra-hepatic. iCCA accounts for 10%-15% of all primary liver cancers worldwide and is the second most common primary liver malignancy after hepatocellular carcinoma with a varying incidence worldwide. There are several risk factors associated with iCCA including older age and female sex. Other risk factors include primary sclerosing cholangitis, hepatolithiasis, choledochal cysts, primary biliary cirrhosis, parasitic biliary infection with Clonorchis sinensis or Opisthorchis viverrini, inflammatory bowel disease, as well as non-alcoholic fatty liver disease. Despite recent developments in imaging modalities and laboratory diagnostic tests, the diagnosis of the tumor is often delayed until advanced stages when surgery cannot be offered. Therefore, iCCA patients generally have poor prognosis with a short overall survival. Treatment of advanced iCCA typically includes systemic therapy with traditional cytotoxic agents, or targeted agents depending on the mutational status of the tumor. For patients with disease amenable to surgery, treatment involves a margin negative hepatic resection, lymphadenectomy, as well as consideration of adjuvant therapy. The objective of this special issue is to characterize the progress made in treating iCCA, as well as highlight the emerging systemic and locoregional treatments of iCCA.

This Special Issue welcomes original or review manuscripts, perspectives, opinions and commentaries on different aspects of iCCA, including but not limited to:
1. Epidemiology
2. Pathogenesis
3. Imaging
4. Role of preoperative chemotherapy
5. Surgical resection and intraoperative considerations
6. Role of lymphadenectomy
7. Use of thermal ablation
8. Hepatic Artery Pump therapy
9. Intra-arterial / Y90 therapy
10. Novel biomarkers
11. Cytotoxic chemotherapy for advanced and adjuvant indications
12.Targeted mutation-based therapy

Submission Deadline

15 Feb 2023

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://hrjournal.net/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=hr&SpecialIssueId=hr220928
Submission Deadline: 15 Feb 2023
Contacts: Ada Zhong, Assistant Editor, editor_Ada@hrjournal.net

Published Articles

none
© 2016-2023 OAE Publishing Inc., except certain content provided by third parties